|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Further, state-of-the-art approaches, such as antibodies to PCKSK9 (proprotein convertase subtilisin-kexin type 9); RNA therapeutics; agents targeting distinct components of the immune/inflammatory response; and novel small molecules that block the actions of RAGE (receptor for advanced glycation end products) signaling, also hold potential as new therapies for diabetes mellitus and cardiovascular disease.
|
30786741 |
2019 |
|
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
The new treatment strategies for lipid-lowering therapy include using proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors as an exciting approach to reduce residual risk of cardiovascular diseases (CVD).
|
27865998 |
2017 |
|
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Autosomal dominant hypercholesterolemia (ADH), characterized by high-plasma low-density lipoprotein cholesterol (LDL-C) levels and premature cardiovascular disease (CVD) risk, is caused by mutations in LDLR, APOB, and/or PCSK9.
|
27919364 |
2017 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
A published Markov model was adopted to investigate lifetime outcomes: (1) number of recurrent CVD events prevented, (2) quality-adjusted life-years (QALYs) gained, (3) costs and (4) incremental cost-effectiveness ratios (ICERs) of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) and ezetimibe added to statin therapy.
|
31243736 |
2019 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Our systematic review included randomised controlled trials if they studied PCSK9 inhibitors in patients for primary and/or secondary prevention of cardiovascular diseases or with hypercholesterolaemia/hyperlipidaemia.
|
30842207 |
2019 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Mechanisms for modulation of those targets are also becoming more diverse while statins remain the backbone of CVD prevention, the new alternatives, such as PCSK9 monoclonals will probably play an important additional role in treatment of patients at risk for CVD.
|
28445176 |
2017 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
High PCSK9 concentrations are associated with an increased risk of cardiovascular disease (CVD).
|
31002780 |
2019 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
In this mini review article we provide an update on the pleiotropic anti-inflammatory properties of approved drugs for use in cardiovascular disease (e.g. antiplatelets, statins, PCSK9 inhibitors) and discuss the role of targeted or untargeted anti-inflammatory atheroprotection in peripheral arterial disease by agents such as colchicine, methotrexate, anti-TNF-α agents and monoclonal antibodies against interleukin-signaling.
|
29169069 |
2018 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review.
|
31832834 |
2019 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
There is no available evidence on the efficacy and safety of PCSK9 inhibitors in non-cardiovascular diseases, particularly cancer.
|
31110520 |
2019 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
We also applied CTM to construct a novel ECL immunosensor and achieve the sensitive detection of the proprotein convertase subtilisin/kexin type 9 (PCSK9), a biomarker related to cardiovascular diseases (CVDs).
|
31794188 |
2020 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
In patients at high cardiovascular disease risk, PCSK9 and Lp(a) are positively and dose-dependently correlated with atorvastatin dosage, whereas the presence of T2D is associated with higher PCSK9 but lower Lp(a) levels.
|
29103916 |
2019 |
|
Cardiovascular Diseases
|
0.200 |
AlteredExpression
|
group |
BEFREE |
The ability of PCSK9 levels to predict cardiovascular disease and prognosis does not seem to apply to a cohort of kidney transplant candidates.
|
30137516 |
2018 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
LDL cholesterol (LDL-C) lowering drugs that operate through the inhibition of PCSK9 are being pursued for the management of hypercholesterolemia and reducing its associated atherosclerotic cardiovascular disease (CVD) risk.
|
30448414 |
2019 |
|
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
In the entire cohort, the third vs first tertile of PCSK9 was not associated with the risk of death from any cause (hazard ratio = 1.09, p = 0.367) and from cardiovascular diseases (hazard ratio = 1.09, p = 0.476).
|
28436724 |
2017 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Hence, design an effective method to detect serum PCSK9 is meaningful for the prevention, monitor and diagnosis of cardiovascular diseases.
|
31513960 |
2019 |
|
Cardiovascular Diseases
|
0.200 |
AlteredExpression
|
group |
BEFREE |
The aim of this review is to outline current findings on the metabolic and dietary regulation of PCSK9 and effects on cholesterol, apoB lipoprotein metabolism, and cardiovascular disease (CVD) risk.
|
28179493 |
2017 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
This study aimed to evaluate the relationship between circulating levels of PCSK9 and arterial stiffness, an early instrumental biomarker of cardiovascular disease risk, in a large sample of overall healthy participants.
|
28468788 |
2017 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
A decade after our discovery of the involvement of proprotein convertase subtilisin/kexin type 9 (PCSK9) in cholesterol metabolism through the identification of the first mutations leading to hypercholesterolemia, PCSK9 has become one of the most promising targets in cholesterol and cardiovascular diseases.
|
25052769 |
2014 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
However, PCSK9 inhibitors are predicted to have weaker effects on VLDL lipids compared with statins for an equivalent lowering of LDL-C, which potentially translate into smaller reductions in cardiovascular disease risk.
|
30524137 |
2018 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of low-density lipoprotein cholesterol and cardiovascular disease risk, and is an emerging therapeutic target.
|
28093849 |
2017 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
A Cochrane review with meta-analysis showed controversial results about the efficacy of PCSK9 antibodies in the prevention of cardiovascular diseases.
|
29334796 |
2018 |
|
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
As such, loss-of-function (LOF) PCSK9 variants that fail to exit the endoplasmic reticulum (ER) increase hepatic LDLR levels and lower the risk of developing CVD.
|
29593095 |
2018 |
|
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Loss-of-function (LOF) mutations of PCSK9 and PCSK9 inhibitors lower low-density lipoprotein cholesterol (LDL-C) and have been associated with a reduced risk of cardiovascular disease.
|
29562810 |
2018 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
The proprotein convertase PCSK9 gene is the third locus implicated in familial hypercholesterolemia, emphasizing its role in cardiovascular diseases.
|
18039658 |
2008 |